Clinical research is in a pivotal moment. Over the past two decades, we’ve witnessed extraordinary advances in biology, genomics, and drug discovery. Yet the infrastructure supporting clinical trial execution has not kept pace. Despite breakthroughs at the molecular level, the operational backbone of drug development remains manually intensive, fractured by point solutions, and heavily reliant on an overstretched workforce.

Artificial intelligence offers a way forward through “AI teammates”: specialised, operationally grounded AI systems designed to work alongside coordinators, clinical operations staff, and sponsor teams to reduce site burden, automate compliance, improve data quality, and ultimately accelerate access to new therapies. From our experience working across sponsors, CROs, and sites, we believe AI teammates are more than simply the next innovation wave. They are quickly becoming a prerequisite for the next chapter of biopharma growth.

The Bottleneck: Not Discovery, But Delivery
The burden of operational complexity has become one of the most limiting factors in modern clinical research. Investigators report that their coordinators are routinely reentering the same data across multiple portals, manually tracking protocol amendments, and juggling redundant documentation requirements.¹,² These are everyday realities that prevent sites from expanding capacity. This is the real crisis. While the industry debates decentralised trial designs or the promise of synthetic control arms, the coordinators at the heart of trial execution are spending late nights reconciling PDFs, formatting logs, and chasing signatures. It’s no wonder that turnover at research sites remains stubbornly high.